Abstract
Despite the existence of a wealth of structural and theoretical data relating to palindromic sequences in the genome, the mechanism of cruciform formation in the presence of anthracyclines in miscellaneous biological processes is still poorly understood. Generally, DNA intercalators influence the DNA superhelicity, which plays a key role in the cruciform formation in DNA molecules. The potential of DNA intercalating ligands on the stabilization/destabilization of cruciform in DNA is discussed. Here, the indirect impact of anthracyclines to cell developing and surviving is analyzed for the first time. Primarily, the anthracycline modifies the helical properties of DNA and the overall DNA structure, and secondarily alters any cruciform-dependent processes, mainly DNA replication and transcription.
Keywords: DNA structure, Anthracyclines, Supercoiling, self-complementary sequence, cruciform motif
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Anthracyclines-Contra Cruciform Extrusion in DNA Regulating Sequences
Volume: 6 Issue: 3
Author(s): Viktor Viglasky
Affiliation:
Keywords: DNA structure, Anthracyclines, Supercoiling, self-complementary sequence, cruciform motif
Abstract: Despite the existence of a wealth of structural and theoretical data relating to palindromic sequences in the genome, the mechanism of cruciform formation in the presence of anthracyclines in miscellaneous biological processes is still poorly understood. Generally, DNA intercalators influence the DNA superhelicity, which plays a key role in the cruciform formation in DNA molecules. The potential of DNA intercalating ligands on the stabilization/destabilization of cruciform in DNA is discussed. Here, the indirect impact of anthracyclines to cell developing and surviving is analyzed for the first time. Primarily, the anthracycline modifies the helical properties of DNA and the overall DNA structure, and secondarily alters any cruciform-dependent processes, mainly DNA replication and transcription.
Export Options
About this article
Cite this article as:
Viglasky Viktor, Anthracyclines-Contra Cruciform Extrusion in DNA Regulating Sequences, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (3) . https://dx.doi.org/10.2174/187153006778250046
DOI https://dx.doi.org/10.2174/187153006778250046 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Current Molecular Medicine Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Cardiovascular & Hematological Disorders-Drug Targets Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Editorial [Hot Topic: Therapeutic Targeting of the Sphingolipid “Biostat” in Hematologic Malignancies (Guest Editors: Thomas P. Loughran and Hong-Gang Wang)]
Anti-Cancer Agents in Medicinal Chemistry The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly
Current Molecular Medicine Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Role of Genetic and Epigenetic Factors in Oral Squamous Cell Carcinoma - A Structured Review
Recent Patents on Biomarkers Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets